相关实验视频

Updated: May 1, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在节点阳性尿路细胞癌中对恩福图马布 (vedotin) 加上 pembrolizumab 的病理完整反应:一个病例报告

Takuto Hara¹, Eiki Inoue², Naoto Wakita¹

¹Department of Urology, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-Cho, Kobe, 650-0017 Japan.

International cancer conference journal

|December 15, 2025

概括

这项案例研究强调了使用恩福图马布维多丁加上布罗利祖马布的晚期尿癌的完整反应. 它表明,手术可能有利于选择对全身治疗有很好的反应的患者.

科学领域:

尿瘤学尿瘤学
新辅助免疫疗法新辅助免疫疗法
手术瘤学手术瘤学

背景情况:

在尿路癌 (UC) 中,先进的结节参与导致不良结果.
仅有有限的证据证明这些患者在免疫治疗后的管理.
关键的新辅助药试验排除了患有大量结节转移的患者.

研究的目的:

介绍一个成功治疗晚期泌尿腺癌的案例.
探索在结节阳性UC中新辅助免疫治疗后手术的作用.

主要方法:

一名76岁的男性患有cT1膀癌,远端尿路UC (≤cT2) 和cN2盆腔淋巴结,接受了恩福图马布维多丁加布罗利祖马布 (EVP).
患者在六次 EVP 循环后实现了放射性完整反应 (CR).
进行了机器人辅助的右侧瘤切除术,并进行了扩展的骨盆淋巴结剖析.

主要成果:

用EVP实现了放射性完整反应 (CR) 和水溶解的解决方案.
病理学证实没有残留癌症 (ypT0,ypN0) 与明显的纤维化,表明强烈的治疗反应.
没有出现手术并发症,并且在手术后停止了全身治疗.

结论:

这是EVP和机器人手术后在节点阳性UC中出现病理完整反应的首例报告.
对于一些晚期UC患者来说,手术可能是可行的选择,这些患者对新辅助全身疗法有很好的反应.
这种方法可以为以前被认为无法切除的患者提供更好的结果.

关键词:

转化手术是一种转化手术.在此之前,Enfortumab 已被注册为 Vedotin.节点阳性疾病节点阳性疾病病理学完整的反应反应.佩姆布罗利兹马布的使用方法尿路细胞癌是什么意思

更多相关视频

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

Published on: May 12, 2019

Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma

Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma

Published on: November 22, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...